Hostname: page-component-78c5997874-8bhkd Total loading time: 0 Render date: 2024-11-05T04:58:54.182Z Has data issue: false hasContentIssue false
  • English
  • Français

Drug Treatment of Epilepsy: When Does It Fail and How to Optimize Its Use?

Published online by Cambridge University Press:  07 November 2014

Patrick Kwan  and
Martin J. Brodie
Get access Rights & Permissions [Opens in a new window]

Abstract

Although modern community-based studies have shown that a majority of people with newly diagnosed epilepsy will enter long-term remission, seizures remain refractory to treatment in a substantial proportion of this population—perhaps as much as 40%. A consensus is being reached that, for operational purposes, pharmacoresistance can be suspected when two appropriately chosen, well-tolerated, first-line antiepileptic drugs (AEDs) or one monotherapy and one combination regimen have failed due to lack of efficacy. Poor prognostic factors include lack of response to the first AED, specific syndromes, symptomatic etiology, family history of epilepsy, psychiatric comorbidity, and high frequency of seizures. These observations suggest that prognosis can often be determined early in the course of the disorder. We propose a management paradigm that aims to maximize the chance of successful AED therapy, including the early use of “rational polytherapy” for patients not responding to monotherapy, and to identify efficiently patients suitable for “curative” resective surgery, in particular those with mesial temporal lobe epilepsy. An orderly approach to each epilepsy syndrome will optimize the chance of perfect seizure control and help more patients achieve a fulfilling life.

Type
Review Article
Information
CNS Spectrums , Volume 9 , Issue 2 , February 2004 , pp. 110 - 119
Copyright
Copyright © Cambridge University Press 2004

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Sander, JW, Shorvon, SD. Epidemiology of the epilepsies. J Neurol Neurosurg Psychiatry. 1996;61:433–43.CrossRefGoogle ScholarPubMed
2.Zarrelli, MM, Beghi, E, Rocca, WA, Hauser, WA. Incidence of epileptic syndromes in Rochester, Minnesota: 1980–1984. Epilepsia. 1999;40:1708–1714.CrossRefGoogle ScholarPubMed
3.Gowers, WR. Epilepsy and Other Chronic Convulsive Diseases. London, England: Churchill; 1881.Google Scholar
4.Rodin, E. The Prognosis of Patients with Epilepsy. Springfield, Ill: Charles C Thomas; 1968.Google Scholar
5.Annegers, JF, Rocca, WA, Hauser, WA. Causes of epilepsy: contributions from the Rochester epidemiology project. Mayo Clin Proc. 1996;71:570–575.CrossRefGoogle ScholarPubMed
6.Hauser, WA, Kurland, LT. The epidemiology of epilepsy in Rochester, Minnesota, 1935 through 1967. Epilepsia. 1975;16:1–66.CrossRefGoogle ScholarPubMed
7.Hauser, WA, Annegers, JF, Kurland, LT. Prevalence of epilepsy in Rochester, Minnesota: 1940-1980. Epilepsia. 1991;32:429–445.CrossRefGoogle ScholarPubMed
8.Hauser, WA, Annegers, JF, Kurland, LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia. 1993;34:453–468.CrossRefGoogle ScholarPubMed
9.Hauser, WA, Annegers, JF, Rocca, WA. Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin Proc. 1996;71:576–586.CrossRefGoogle ScholarPubMed
10.Annegers, JF, Hauser, WA, Elverhack, LR. Remission of seizures and relapse in patients with epilepsy. Epilepsia. 1979;20:729–737.CrossRefGoogle ScholarPubMed
11.Shafer, SQ, Hauser, WA, Annegers, JF, Klaus, DW. EEG and other early predictors of epilepsy remission: a community study. Epilepsia. 1988;29:590–600.CrossRefGoogle ScholarPubMed
12.Hart, YM, Sander, JW, Shorvon, SD. National General Practice Study of Epilepsy and Epileptic Seizures: objectives and study methodology of the largest reported prospective cohort study of epilepsy. Neuroepidemiology. 1989;8:221–227.Google ScholarPubMed
13.Cockerell, OC, Johnson, AL, Sander, JW, Hart, YM, Shorvon, SD. Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet. 1995;346:140–144.CrossRefGoogle ScholarPubMed
14.MacDonald, BK, Johnson, AL, Goodridge, DM, Cockerell, OC, Sander, JW, Shorvon, SD. Factors predicting prognosis of epilepsy after presentation with seizures. Ann Neurol. 2000;48:833–841.3.0.CO;2-U>CrossRefGoogle ScholarPubMed
15.Elwes, RD, Johnson, AL, Shorvon, SD, Reynolds, EH. The prognosis for seizure control in newly diagnosed epilepsy. N Engl J Med. 1984;311:944–947.CrossRefGoogle ScholarPubMed
16.Collaborative Group for the Study of Epilepsy. Prognosis of epilepsy in newly referred patients: a multicenter prospective study of the effects of monotherapy on the long-term course of epilepsy. Epilepsia. 1992;33:45–51.CrossRefGoogle Scholar
17.Sillanpää, M, Jalava, M, Kaleva, O, Shinnar, S. Long-term prognosis of seizures with onset in childhood. N Engl J Med. 1998;338:1715–1722.CrossRefGoogle ScholarPubMed
18.Perucca, E. Pharmacoresistance in epilepsy: how should it be defined? CNS Drugs. 1998;10:171–179.CrossRefGoogle Scholar
19.Regesta, G, Tanganelli, P. Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res. 1999;34:109–122.CrossRefGoogle ScholarPubMed
20.Kwan, P, Brodie, MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314–319.CrossRefGoogle ScholarPubMed
21.Kwan, P, Brodie, MJ. Effectiveness of first antiepileptic drug. Epilepsia. 2001;42:1255–1260.CrossRefGoogle ScholarPubMed
22.Dlugos, DJ, Sammel, MD, Strom, BL, Farrar, JT. Response to first drug trial predicts outcome in childhood temporal lobe epilepsy. Neurology. 2001;57:2259–2264.CrossRefGoogle ScholarPubMed
23.Mohanraj, R, Brodie, MJ. Prediction of refractory epilepsy. Epilepsia. 2003;44(suppl 8):156.Google Scholar
24.Brodie, MJ, Mohanraj, R. Pharmacological outcomes in newly diagnosed epilepsy. Epilepsia. 2003;44(suppl 8):84.Google Scholar
25.Brodie, MJ, Kwan, P. Staged approach to epilepsy management. Neurology 2002;58(supp1 5):S2–S8.CrossRefGoogle ScholarPubMed
26.Arts, WF, Geerts, AT, Brouwer, OF, Peters, ACB, Stroink, H, van Donselaar, CA. The early prognosis of epilepsy in childhood: the prediction of a poor outcome. The Dutch study of epilepsy in childhood. Epilepsia. 1999;40:726–734.CrossRefGoogle ScholarPubMed
27.Berg, AT, Shinnar, S, Levy, SR, Testa, FM, Smith-Rapaport, S, Beckerman, B. Early development of intractable epilepsy in children: a prospective study. Neurology. 2001;56:1445–1452.CrossRefGoogle ScholarPubMed
28.Engel, J Jr.Surgery for seizures. N Engl J Med. 1996;334:647–652.CrossRefGoogle ScholarPubMed
29.Engel, J Jr.Introduction to temporal lobe epilepsy. Epilepsy Res. 1996;26:141–150.CrossRefGoogle ScholarPubMed
30.Berg, AT, Shinnar, S, Levy, SR, et al.Defining seizure outcomes in pediatric epilepsy: the good, the bad and the in-between. Epilepsy Res. 2001;43:75–84.CrossRefGoogle ScholarPubMed
31.Berg, AT, Shinnar, S, Levy, SR, et al.Two-year remission and subsequent relapse in children with newly diagnosed epilepsy. Epilepsia. 2001;42:1553–1562.CrossRefGoogle ScholarPubMed
32.Semah, F, Picot, M-C, Adam, C, et al.Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology. 1998;51:1256–1262.CrossRefGoogle Scholar
33.Stephen, LJ, Kwan, P, Brodie, MJ. Does the cause of localization-related epilepsy influence the response to antiepileptic drug treatment? Epilepsia. 2001;42:357–362.CrossRefGoogle ScholarPubMed
34.Fuerst, D, Shah, J, Shah, A, Watson, C. Hippocampal sclerosis is a progressive disorder: a longitudinal volumetric MRI study. Ann Neural. 2003;53:413–416.CrossRefGoogle ScholarPubMed
35.Kobayashi, E, Lopes-Cendes, I, Guerreiro, CA, Sousa, SC, Guerreiro, MM, Cendes, F. Seizure outcome and hippocampal atrophy in familial mesial temporal lobe epilepsy. Neurology. 2001;56:166–172.CrossRefGoogle ScholarPubMed
36.Berg, AT, Langfitt, J, Shinnar, S, et al.How long does it take for partial epilepsy to become intractable? Neurology. 2003;60:186–190.CrossRefGoogle ScholarPubMed
37.Meldrum, BS. Why and when are seizures bad for the brain? TIPS. 2001;22:445–446.Google ScholarPubMed
38.Sutula, TP, Hagen, J, Pitkanen, A. Do epileptic seizures damage the brain? Curr Opin Neurol. 2003;16:189–195.CrossRefGoogle ScholarPubMed
39.Kwan, P, Brodie, MJ. Refractory epilepsy: a progressive, intractable hut preventable condition? Seizure 2002;11:77–84.CrossRefGoogle Scholar
40.Shorvon, SD, Reynolds, EH. Reduction in polypharmacy for epilepsy. Br Med J. 1979;2:1023–1025.CrossRefGoogle ScholarPubMed
41.Schmidt, D. Reduction of two-drug therapy in intractable epilepsy. Epilepsia. 1983;24:368–376.CrossRefGoogle ScholarPubMed
42.Mohanraj, R, Brodie, MJ. Measuring the efficacy of antiepileptic drugs. Seizure. 2003;12:413–443.CrossRefGoogle ScholarPubMed
43.Brodie, MJ, French, JA. Management of epilepsy in adolescents and adults. Lancet. 2000;356:323–329.CrossRefGoogle ScholarPubMed
44.Appleton, RE, Peters, AC, Mumfotd, JP, Shaw, DE. Randomised, placebo-controlled study of vigabatrin as first-line tteatment of infantile spasms. Epilepsia. 1999;40:1627–1633.CrossRefGoogle Scholar
45.Taylor, S, Tudur Smith, C, Williamson, PR, Marson, AG. Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalized onset tonic-clonic seizures. Cochrane Database Syst Rev. 2001;4:CD002217.Google Scholar
46.Marson, AG, Williamson, PR, Hutton, JL, et al.Carbamazepine versus valproate monotherapy for epilepsy: a meta-analysis. Epilepsia. 2002;43:505–513.CrossRefGoogle ScholarPubMed
47.Tudur Smith, C, Marson, AG, Williamson, PR. Phenytoin versus valproate monotherapy for partial onset seizures and generalized onset tonic-clonic seizures. Cochrane Database Syst Rev. 2001;4:CD0017690.CrossRefGoogle Scholar
48.Tudur Smith, C, Marson, AG, Clough, HE, Williamson, PR. Carbamazepine versus phenytoin monotherapy for epilepsy. Cochrane Database Syst Rev. 2002;2:CDO01911.CrossRefGoogle Scholar
49.Kwan, P, Brodie, MJ. Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy. Neurology. 2003;60(suppl 4):S2–S12.CrossRefGoogle ScholarPubMed
50.Chadwick, D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicenter randomised double-blind study. Vigabatrin European Monotherapy Study Group. Lancet. 1999;354:13–19.CrossRefGoogle ScholarPubMed
51.Kwan, P, Brodie, MJ. Neuropsychological effects of epilepsy and antiepileptic drugs. Lancet. 2001;357:216–222.CrossRefGoogle ScholarPubMed
52.Brodie, MJ, Richens, A, Yuen, AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet. 1995;345:476–479.CrossRefGoogle ScholarPubMed
53.Brodie, MJ, Overstall, PW, Giorgi, L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res. 1999;37:81–87.CrossRefGoogle ScholarPubMed
54.Guerreiro, MM, Vigonius, U, Pohlmann, H, et al.A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res. 1997;27:205–213.CrossRefGoogle ScholarPubMed
55.Arroya, S, De la Morena, A. Life-threatening adverse events of antiepileptic drugs. Epilepsy Res. 2001;47:155–174.CrossRefGoogle Scholar
56.Schmidt, D, Gram, L. Monotherapy versus polythetapy in epilepsy. A reappraisal. CNS Drugs. 1995;3:194–208.CrossRefGoogle Scholar
57.Lammers, MW, Hekster, YA, Keyser, A, Meinardi, H, Renier, WO, van Lier, H. Monotherapy or polytherapy for epilepsy revisited: a quantitative assessment. Epilepsia. 1995;36:440–446.CrossRefGoogle ScholarPubMed
58.Kwan, P, Brodie, MJ. Epilepsy after the first drug fails: substitution or add-on? Seizure. 2000;9:464–468.CrossRefGoogle ScholarPubMed
59.Deckers, CLP, Hekster, YA, Keyser, A, van Lier, HJ, Meinardi, H, Renier, WO. Monotherapy versus polytherapy for epilepsy: a multicenter double-blind randomized study. Epilepsia. 2001;42:1387–1394.CrossRefGoogle ScholarPubMed
60.Lindberger, M, Alenius, M, Frisen, L, et al.Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomized, double-blind, dose titration study. GREAT Study Investigators Group. Gabapentin in Refractory Epilepsy Add-on Treatment. Epilepsia. 2000;41:1289–1295.CrossRefGoogle Scholar
61.Marson, AG, Kadir, ZA, Hutton, JL, et al.The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia. 1997;38:859–880.CrossRefGoogle ScholarPubMed
62.Marson, AG, Hutton, JL, Leach, JP, et al.Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilepsy Res. 2001;46:259–270.CrossRefGoogle ScholarPubMed
63.Deckers, CLP, Czuczwar, SJ, Hekster, YA, et al.Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia. 2000;41:1364–1374.CrossRefGoogle ScholarPubMed
64.Kwan, P, Sills, GJ, Brodie, MJ. The mechanisms of action of commonly used antiepileptic drugs. Pharmacol Ther. 2001;90:21–34.CrossRefGoogle ScholarPubMed
65.Sills, GJ, Brodie, MJ. Update on the mechanisms of action of antiepileptic drugs. Epileptic Disord. 2001;3:165–172.Google ScholarPubMed
66.Sun, M, van Rijn, CM, Liu, Y, Wang, M. Combination of carbamazepine and valproate in different dose proportions in maximal electroshock seizure model in mice. Epilepsy Res. 2002;51:5–11.CrossRefGoogle ScholarPubMed
67.Luszczki, JJ, Borowicz, KK, Swiader, M, Czuczwar, SJ. Interactions between oxcarbazepine and conventional antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia. 2003;44:489–499.CrossRefGoogle ScholarPubMed
68.Brodie, MJ, Yuen, AW. Lamotrigine substitution study: synergism with sodium valproate? The 105 Study Group. Epilepsy Res. 1997;26:423–432.CrossRefGoogle ScholarPubMed
69.Pisani, F, Otero, G, Russo, MF, Di Perri, R, Perucca, E, Richens, A. The efficacy of valproate-lamotrigine comedicatoin in refractory complex partial seizures: evidence fora pharmacodynamic interaction. Epilepsia. 1999;40:1141–1146.CrossRefGoogle Scholar
70.Brodie, MJ. Management strategies for refractory localization-related seizures. Epilepsia. 2001;42(suppl 3):27–30.CrossRefGoogle ScholarPubMed
71.Rowan, AJ, Meijer, JW, de Beer-Pawlikowski, N, et al.Valproate ethosuximide combination therapy for refractory absence seizures. Arch Neurol. 1983;40:797–802.CrossRefGoogle ScholarPubMed
72.Brodie, MJ, Mumford, JP. Double-blind substitution of vigabatrin and valproate in carbamazepine-resistant partial epilepsy. The 012 Study Group. Epilepsy Res. 1999;34:199–205CrossRefGoogle ScholarPubMed
73.Stephen, LJ, Sills, GJ, Brodie, MJ. Lamotrigine and topiramate may be a useful combination. Lancet. 1998;351:958–959.CrossRefGoogle ScholarPubMed
74.Brodie, MJ, Kwan, P. The star systems: overview and use in determining antiepileptic drug choice. CNS Drugs. 2001;15:1–12.CrossRefGoogle ScholarPubMed
75.Stephen, LJ, Brodie, MJ. Seizure freedom with more than one antiepileptic drug. Seizure. 2002;11:349–351.CrossRefGoogle ScholarPubMed
76.Brodie, MJ, Leach, JP. Success or failure with antiepileptic drug therapy: beyond empiricism? Neurology. 2003;60:162–163.CrossRefGoogle ScholarPubMed
77.Siddiqui, A, Kerb, R, Weale, ME, et al.Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med. 2003;348:1442–1448.CrossRefGoogle ScholarPubMed